Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRASG12D-mutant pancreatic ductal adenocarcinoma

[1]  P. Lobie,et al.  Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple negative breast cancer , 2024, NPJ precision oncology.

[2]  ChunYan Zhao,et al.  Wild-type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β-catenin pathway , 2022, Molecular medicine reports.

[3]  Chien-Chih Chiu,et al.  Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components , 2022, Frontiers in Molecular Biosciences.

[4]  H. Kolbeinsson,et al.  Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. , 2022, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[5]  T. Zhu,et al.  Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma , 2022, Communications Medicine.

[6]  Hui Guo,et al.  Trefoil factor 3 promotes pancreatic carcinoma progression via WNT pathway activation mediated by enhanced WNT ligand expression , 2022, Cell Death & Disease.

[7]  T. Zhu,et al.  Mitochondria: The metabolic switch of cellular oncogenic transformation. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[8]  S. C. Chafe,et al.  Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer , 2020, Cell reports. Medicine.

[9]  L. Leung,et al.  The livestock growth-promoter zeranol facilitates GLUT4 translocation in 3T3 L1 adipocytes. , 2020, Chemosphere.

[10]  J. Kirkwood,et al.  Clinical Development of BRAF plus MEK Inhibitor Combinations. , 2020, Trends in cancer.

[11]  F. McCormick,et al.  RAS-targeted therapies: is the undruggable drugged? , 2020, Nature Reviews Drug Discovery.

[12]  M. Barbacid,et al.  Targeting the MAPK Pathway in KRAS-Driven Tumors. , 2020, Cancer cell.

[13]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[14]  J. Ross,et al.  Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. , 2019, Gastroenterology.

[15]  W. Kolch,et al.  Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation , 2019, British Journal of Cancer.

[16]  P. Savoia,et al.  Targeting the ERK Signaling Pathway in Melanoma , 2019, International journal of molecular sciences.

[17]  F. Ciardiello,et al.  Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines , 2019, Journal of Experimental & Clinical Cancer Research.

[18]  P. Timpson,et al.  Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine , 2018, Gut.

[19]  Basappa,et al.  Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation , 2018, Proceedings of the National Academy of Sciences.

[20]  Channing J Der,et al.  KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. , 2018, Cold Spring Harbor perspectives in medicine.

[21]  R. Kefford,et al.  Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma , 2018, Oncogenesis.

[22]  Shu-mei Lin,et al.  Co‐administrating apigenin in a high‐cholesterol diet prevents hypercholesterolaemia in golden hamsters , 2018, The Journal of pharmacy and pharmacology.

[23]  Basappa,et al.  Bad phosphorylation as a target of inhibition in oncology. , 2018, Cancer letters.

[24]  D. Morrison,et al.  Targeting the Raf kinases in human cancer: the Raf dimer dilemma , 2017, British Journal of Cancer.

[25]  W. Hahn,et al.  Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma , 2017, JAMA oncology.

[26]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.

[27]  P. Philip,et al.  Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial , 2017, JAMA oncology.

[28]  C. Der,et al.  The role of wild type RAS isoforms in cancer. , 2016, Seminars in cell & developmental biology.

[29]  E. Petricoin,et al.  Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. , 2016, Cancer cell.

[30]  C. Der,et al.  Targeting RAS-mutant cancers: is ERK the key? , 2015, Trends in cancer.

[31]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[32]  D. Mukherji,et al.  Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers , 2015, International journal of molecular sciences.

[33]  D. Planchard,et al.  A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  J. Devière,et al.  New challenges in perioperative management of pancreatic cancer. , 2015, World journal of gastroenterology.

[35]  Antonio Marchetti,et al.  The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies , 2015, Nature Genetics.

[36]  A. Tolcher,et al.  A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  A. Letai,et al.  RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis , 2014, Science Signaling.

[38]  Joon-Oh Park,et al.  A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. , 2014, European journal of cancer.

[39]  Andreas Schlicker,et al.  Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. , 2014, Cell reports.

[40]  M. Washington,et al.  Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway , 2014, British Journal of Cancer.

[41]  Ariana Peck,et al.  Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers , 2013, Nature.

[42]  G. Tortora,et al.  Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy , 2013, Front. Pharmacol..

[43]  David R McIlwain,et al.  Caspase functions in cell death and disease. , 2013, Cold Spring Harbor perspectives in biology.

[44]  S. Chandarlapaty,et al.  Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. , 2012, Cancer cell.

[45]  T. Ciuleanu,et al.  A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy , 2012, Investigational New Drugs.

[46]  M. Kanda,et al.  Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. , 2012, Gastroenterology.

[47]  John V Heymach,et al.  Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. , 2012, Journal of the National Cancer Institute.

[48]  Tae-You Kim,et al.  A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens , 2011, Investigational New Drugs.

[49]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[50]  Xiaowen Zhang,et al.  Deleted in pancreatic carcinoma locus 4/Smad4 participates in the regulation of apoptosis by affecting the Bcl-2/Bax balance in non-small cell lung cancer. , 2008, Human pathology.

[51]  Neal Rosen,et al.  The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. , 2005, Cancer cell.

[52]  P. Koskinen,et al.  Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site , 2004, FEBS letters.

[53]  P. Cohen,et al.  Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. , 2000, The Biochemical journal.

[54]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[55]  Manuel Hidalgo,et al.  Addressing the challenges of pancreatic cancer: future directions for improving outcomes. , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].